A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/485 (2006.01) A61K 31/19 (2006.01) A61K 31/195 (2006.01) A61K 31/22 (2006.01) A61K 31/24 (2006.01) A61K 31/415 (2006.01) A61K 31/445 (2006.01)
Patent
CA 2119033
2119033 9305775 PCTABS00021 A method of attenuating the symptoms of opioid withdrawal in a human or animal subject comprises administering to the subject an effective opioid withdrawal symptom attenuating amount of an inhibitor of nitric oxide synthase (NOS) for a period of time effective to attenuate such symptoms upon opioid withdrawal. NOS inhibitors useful in the present method include, for example, L-NG-nitroarginine, esters of L-NG-nitroarginine, L-NG-monomethylarginine, L-NG-benzylarginine, L-NG-aminoarginine, iminoethylornithine, and pharmaceutically acceptable salts thereof. These compounds can be used alone or in combination, in conjunction with conventional drugs, such as .alpha.2-adrenoceptor agonists, mixed agonist-antagonist opioids, and NMDA antagonists, to attenuate the symptoms of opioid withdrawal. Effective doses of NOS inhibitors range from about 1 µg/kg/day to about 30mg/kg/day, administered over the course of about 1 hour to about six days, followed by opioid withdrawal.
Kimes Alane S.
London Edythe D.
Department Of Health And Human Services (the)
Fetherstonhaugh & Co.
LandOfFree
Attenuation of the opioid withdrawal syndrome by inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuation of the opioid withdrawal syndrome by inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuation of the opioid withdrawal syndrome by inhibitors... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1686578